dr. sequist on pembrolizumab monotherapy in nonsquamous nsclc
Published 5 years ago • 131 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
1:39
dr. sequist on implications of the impower150 trial in advanced nonsquamous nsclc
-
1:50
dr. levy discusses pembrolizumab in nsclc
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
4:05
pembrolizumab chemotherapy in newly diagnosed nsclc
-
2:13
dr. malhotra on pembrolizumab during concurrent chemoradiation in nsclc
-
1:53
dr. spigel on pembrolizumab/chemo combo in first-line nsclc
-
3:47
pembrolizumab as treatment for oligometastatic nsclc
-
2:20
dr. gadgeel on pembrolizumab/chemo combo in nsclc
-
0:58
dr. sequist distinguishes osimertinib from earlier nsclc tkis
-
1:15
dr. spigel on fda approval of pembrolizumab/chemo combo in nsclc
-
6:11
pembrolizumab: monotherapy versus combination therapy
-
1:14
dr. herbst on long term survival with pembrolizumab in nsclc
-
1:04
dr. gutierrez on the safety profile of pembrolizumab-based combos in nsclc
-
5:00
implications for pembrolizumab in nsclc
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
1:00
dr. papadimitrakopoulou provides an update on pembrolizumab for lung cancer
-
4:02
immunotherapy options for lung cancer variations
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
5:54
pembrolizumab in newly diagnosed squamous nsclc